Ginkgo Bioworks (NYSE: DNA) is a publicly traded DNA Synthesis & Biofoundries company founded in 2008 and based in Boston, United States.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
Ginkgo Bioworks reported Q2 2026 revenue of $20 million, down 48% year-over-year from $39 million, driven by ongoing program rationalization as part of restructuring activities. The company posted a GAAP net loss from continuing operations of $57 million versus $53 million in Q2 2025. Adjusted EBITDA loss was $36 million, worsening from $25 million loss in the prior year. Cash and marketable securities totaled $302 million as of June 30, 2026. On operations, Ginkgo won government contracts to build autonomous labs at MIT, Caltech, Northwestern, and University of Maryland under NSF's $400 million cloud lab initiative, and began a $47 million autonomous lab project at Pacific Northwest National Laboratory. Nebula, the company's autonomous lab, is scaling rapidly with 100+ robots running experiments continuously. The new ADME-One pharma service launched with 17 customer signings in six weeks. Full-year 2026 cash burn guidance remains ($150)–($125) million.
Full-year 2026 cash burn of ($150)–($125) million

Shanghai bio-tech leaders debut an AI-assisted platform for protein synthesis.
Ginkgo Bioworks posts a Q1 revenue decline and reaffirms its cash-burn outlook.
Ginkgo Bioworks' Q1 2026 revenue falls and the company discloses restructuring efforts.

Ginkgo Bioworks' stock has fallen to penny-stock territory, raising questions about its valuation and market performance.

Ginkgo Bioworks dropped from the Russell 3000E Growth Benchmark.

Ginkgo Bioworks is removed from the Russell 2000 Growth Index.
An automated, high-throughput cell-programming platform that designs, builds, and tests engineered microbes and cells for partners. Customers across pharmaceutical, agricultural, food, and industrial sectors use the Foundry to develop novel enzymes, strains, and biological products without building their own lab infrastructure. The Foundry combines robotics, software, and a large library of genetic parts to iterate on organism designs at scale, sold as a research-and-development service.
Launched in September 2024, Datapoints generates large, high-quality biological datasets with fast turnaround and competitive per-datapoint pricing, aimed at training AI and machine-learning models in biology. It targets biopharma and AI teams that need experimentally generated, structured lab data to power lab-in-the-loop workflows and model development. The service packages Ginkgo's automation and assay capacity into a data-generation offering distinct from its organism-engineering work.
A biosecurity arm building infrastructure and technologies to help governments and global institutions predict, detect, and respond to biological threats. It deploys pathogen monitoring at airports and other points of entry, environmental and wastewater surveillance, and bioinformatics tools to flag emerging risks. The unit positions Ginkgo's sequencing and data capabilities as a public-health and national-security service alongside its commercial foundry business.
7 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗